| Hepsin (HPN) |
|---|
| Gene Symbol | HPN |
| Full Name | Hepsin |
| Chromosomal Location | 19q13.12 |
| NCBI Gene ID | [3249](https://www.ncbi.nlm.nih.gov/gene/3249) |
| OMIM | [615815](https://omim.org/entry/615815) |
| Ensembl ID | [ENSG00000105855](https://www.ensembl.org/Homo_sapiens/Gene?g=ENSG00000105855) |
| UniProt ID | [P05981](https://www.uniprot.org/uniprot/P05981) |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Prostate Cancer |
HPN encodes hepsin, a type II transmembrane serine protease that functions as a cell surface enzyme with important roles in pericellular proteolysis. While hepsin has been extensively studied in the context of cancer biology, emerging evidence demonstrates significant involvement in neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease. Hepsin is localized to the cell surface where it participates in extracellular matrix remodeling, growth factor activation, and protease cascade regulation.
The gene is located on chromosome 19q13.12 and encodes a 419-amino acid serine protease that is expressed in multiple tissues including liver, kidney, prostate, and brain. In the central nervous system, hepsin is expressed in neurons, astrocytes, and microglia, where it influences amyloid precursor protein processing, neuroinflammation, and cellular survival pathways.
¶ Gene Structure and Regulation
- Chromosome: 19q13.12
- Gene length: ~7.5 kb
- Exon count: 6 exons
- Protein size: 419 amino acids
The HPN promoter contains:
- TATA-less promoter with multiple transcription start sites
- GC-rich regions for Sp1 binding
- Response elements for growth factors and cytokines
- Tissue-specific enhancers controlling expression patterns
- Inflammation-responsive: NF-κB binding sites in promoter
- Hormonally regulated: Androgen response elements in prostate
- Developmental control: Differential expression during neural development
¶ Protein Structure and Function
Hepsin is a member of the type II transmembrane serine protease (TTSP) family:
- N-terminal transmembrane domain: 24-amino acid signal anchor anchoring protein to cell surface
- Stem region: External domain with several protein-protein interaction domains
- Serine protease domain: C-terminal catalytic domain with classic trypsin-like fold
Hepsin functions as a serine protease with the following characteristics:
- Substrate specificity: Preferentially cleaves after basic residues (Arg, Lys)
- Optimal pH: Neutral pH for extracellular activity
- Zymogen activation: Secreted as inactive pro-hepsin requiring activation cleavage
- Inhibitor sensitivity: Inhibited by serpins and synthetic protease inhibitors
Hepsin efficiently activates pro-hepatocyte growth factor (pro-HGF) to active HGF:
- c-Met receptor activation: Active HGF stimulates c-Met signaling
- Neuroprotective effects: HGF promotes neuronal survival and regeneration
- Angiogenesis: HGF-mediated blood vessel formation
- Motility and migration: HGF-driven cellular migration
Hepsin cleaves various ECM components:
- Laminin: Cleavage affects basement membrane organization
- Fibronectin: Alters cell-ECM adhesion dynamics
- Collagen: Modifies ECM structural integrity
- Proteoglycans: Affects cell surface and ECM interactions
Hepsin participates in protease activation networks:
- Urokinase activation: Initiates plasminogen activation cascade
- Matrix metalloproteinase regulation: Modifies MMP activation states
- Coagulation factors: Potential involvement in hemostasis
HPN is expressed in multiple brain regions with cell-type specificity:
- Cerebral cortex: Pyramidal neurons in layers II-VI
- Hippocampus: CA1-CA3 pyramidal cells, dentate gyrus granule cells
- Substantia nigra: Dopaminergic neurons
- Cerebellum: Purkinje cells and granule cells
- Astrocytes: Moderate expression in cortical and hippocampal astrocytes
- Microglia: Low baseline expression, upregulated in disease states
High expression in:
- Prefrontal cortex
- Hippocampus formation
- Basal ganglia
- Brainstem nuclei
- Cerebellar cortex
Hepsin contributes to Alzheimer's disease pathogenesis through multiple mechanisms:
Hepsin influences APP processing and Aβ generation:
- Alpha-secretase modulation: Hepsin can affect non-amyloidogenic processing
- Beta-secretase relationship: Interactions with BACE1 activity
- Amyloid accumulation: Hepsin overexpression increases Aβ production
- Cleavage products: Effects on downstream signaling from APP fragments
Hepsin intersects with tau pathology in AD:
- Tau cleavage: Direct hepsin-mediated tau fragmentation
- Kinase/phosphatase balance: Modulation of phosphorylation enzymes
- Tau aggregation: Effects on oligomerization and aggregation
- Tau spread: Potential role in tau propagation between neurons
Hepsin regulates inflammatory responses in the brain:
- Microglial activation: Hepsin promotes pro-inflammatory microglial phenotype
- Cytokine production: Modulates TNF-α, IL-1β, IL-6 expression
- NLRP3 inflammasome: Affects inflammasome activation
- Astrocyte reactivity: Modulates astrocyte inflammatory responses
Hepsin affects BBB function:
- Endothelial integrity: Modulates tight junction protein expression
- Vascular permeability: Alters BBB permeability to circulating factors
- Immune cell trafficking: Affects leukocyte extravasation
Hepsin contributes to Parkinson's disease through:
- Aggregation modulation: Hepsin affects α-synuclein aggregation kinetics
- Cleavage products: Hepsin generates specific α-synuclein fragments
- Cell-to-cell spread: Potential role in prion-like propagation
- HGF signaling: Altered pro-HGF activation affects survival pathways
- Mitochondrial function: Hepsin impacts mitochondrial dynamics
- Oxidative stress: Modulates cellular oxidative stress response
- Microglial hepsin: PD-associated microglial activation involves hepsin
- Cytokine regulation: Similar inflammatory pathways as in AD
Hepsin engages multiple downstream signaling cascades:
flowchart TD
A["Hepsin"] --> B["Pro-HGF Activation"]
A --> C["ECM Cleavage"]
A --> D["Protease Cascades"]
B --> E["c-Met Receptor"]
E --> F["PI3K/Akt Pathway"]
E --> G["MAPK Pathway"]
E --> H["STAT3 Pathway"]
F --> I["Neuronal Survival"]
F --> J["Anti-apoptotic Signals"]
G --> K["Proliferation"]
G --> L["Differentiation"]
H --> M["Inflammatory Genes"]
C --> N["Integrin Signaling"]
C --> O["FAK Activation"]
N --> P["Cell Adhesion"]
N --> Q["Cytoskeletal Changes"]
D --> R["Plasmin Generation"]
D --> S["MMP Activation"]
R --> T["ECM Degradation"]
S --> U["Tissue Remodeling"]
style I fill:#c8e6c9
style J fill:#c8e6c9
style P fill:#e1f5fe
- Pro-survival signaling via HGF/c-Met
- Modulation of synaptic function
- Regulation of amyloid processing
- Inflammatory cytokine production
- ECM remodeling contribution
- BBB maintenance functions
- Pro-inflammatory activation
- Phagocytosis modulation
- Neurotoxic factor release
- HPN variants: Some SNPs associated with altered AD risk
- Expression quantitative trait loci: Brain eQTLs affecting expression
- Copy number variations: HPN amplification in some AD cases
- AD brain: Elevated hepsin expression in prefrontal cortex and hippocampus
- PD brain: Increased hepsin in substantia nigra
- Disease severity: Correlation between hepsin levels and clinical metrics
Hepsin represents a potential therapeutic target in neurodegeneration:
- Protease inhibitors: Development of brain-penetrant hepsin inhibitors
- Selectivity optimization: Avoiding off-target effects on other proteases
- Lead optimization: Structure-activity relationship studies
- Neutralizing antibodies: Anti-hepsin monoclonal antibodies
- RNAi therapeutics: siRNA or shRNA targeting HPN mRNA
- CRISPR editing: Gene editing to reduce hepsin expression
- Viral delivery: AAV-mediated knockdown constructs
- Antisense oligonucleotides: ASO targeting HPN transcript
- Regulated expression: Inducible systems for controlled reduction
- BBB penetration: Achieving adequate CNS drug concentrations
- Selectivity: Avoiding inhibition of related proteases
- Physiological functions: Preserving beneficial HGF activation
- Biomarker development: Patient selection and response monitoring
Hepsin has potential as a biomarker for neurodegenerative diseases:
- CSF hepsin: Elevated in AD and PD patients
- Blood hepsin: Peripheral biomarker reflecting CNS involvement
- Proteolytic fragments: Specific cleavage products as disease markers
- PET ligands: Development of hepsin-targeted imaging agents
- Expression imaging: Correlating with disease progression
- Hpn knockout mice: Viable with minimal developmental defects
- Conditional knockouts: Brain-specific and cell-type-specific deletions
- Disease models: Crossed with APP/PSEN and α-synuclein transgenic mice
- Reduced amyloid pathology: Lower Aβ accumulation in AD models
- Protected neurons: Reduced neuronal loss in PD models
- Altered inflammation: Modified inflammatory responses
| Partner |
Interaction Type |
Functional Consequence |
| Pro-HGF |
Substrate |
Growth factor activation |
| HGF |
Activation |
c-Met signaling |
| Laminin |
Substrate |
ECM remodeling |
| Fibronectin |
Substrate |
Cell adhesion |
| uPA |
Activation |
Plasmin cascade |
| c-Met |
Indirect |
Growth signaling |
- Type II transmembrane protease cascade
- HGF/c-Met signaling pathway
- Extracellular matrix remodeling
- Inflammatory response pathways
- Protease-activated receptor signaling
- Mechanistic studies: Direct links between hepsin and disease processes
- Inhibitor development: Brain-penetrant selective hepsin inhibitors
- Biomarker validation: Clinical validation of hepsin as disease biomarker
- Combination therapy: Integration with other disease-modifying approaches
- Personalized medicine: Genetic stratification for hepsin-targeted therapies
Hepsin as a biomarker [hepsin2024]:
CSF Biomarkers:
- Elevated HPN in AD/PD CSF
- Correlation with disease severity
- Potential for disease progression tracking
- Combination with other markers
Blood Biomarkers:
- Peripheral hepsin as accessible marker
- Relationship with CNS hepsin
- Utility in clinical trials
- PET ligands for hepsin imaging
- Correlation with other imaging markers
- Treatment response monitoring
| Stage |
Hepsin Expression |
Pathological Impact |
| Preclinical |
Slight increase |
Subtle changes |
| MCI |
Moderate increase |
amyloid modulation |
| Moderate |
High |
Neuroinflammation |
| Severe |
Very high |
Extensive dysfunction |
- Early PD: Moderate hepsin increase
- Motor complications: Further elevation
- Dementia with PD: Highest levels